Open AccessEconomic burden in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), with or without brain metastases, receiving first-line ALK inhibitors
Author(s) -
Yanyu Wu,
Kaili Ren,
Yin Wan,
Huamao Mark Lin
Publication year - 2022
Publication title -
journal of oncology pharmacy practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.548
H-Index - 34
eISSN - 1477-092X
pISSN - 1078-1552
DOI - 10.1177/10781552221126174
Subject(s) - medicine , anaplastic lymphoma kinase , alk inhibitor , lung cancer , odds ratio , confidence interval , oncology , health care , anaplastic large cell lymphoma , cancer , lymphoma , emergency medicine , economic growth , malignant pleural effusion , economics